Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer
Pharmaceutics · 11.09.2024 · 16 (9) · 1196
DOI: 10.3390/pharmaceutics16091196 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 11.09.2024. Verfasst von Mafalda Calheiros-Lobo und 5 weiteren Autor:innen. Beteiligte Einrichtung: UNIPRO-Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e …. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 246 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cooperativa de Ensino Superior Politécnico e Universitário Crl (CESPU), CESPU—Cooperativa de Ensino Superior Politécnico e Univer- sitário Crl, CESPU.
Abstract (Originalsprache)
Head and neck cancer (HNC), the sixth most common cancer worldwide, is increasing in incidence, with oral squamous cell carcinoma (OSCC) as the predominant subtype. OSCC mainly affects middle-aged to elderly males, often occurring on the posterior lateral border of the tongue, leading to significant disfigurement and functional impairments, such as swallowing and speech difficulties. Despite advancements in understanding OSCC’s genetic and epigenetic variations, survival rates for advanced stages remain low, highlighting the need for new treatment options. Primary treatment includes surgery, often combined with radiotherapy (RT) and chemotherapy (CT). Cetuximab-based chemotherapy, targeting the overexpressed epidermal growth factor receptor (EGFR) in 80–90% of HNCs, is commonly used but correlates with poor prognosis. Additionally, monopolar spindle 1 (MPS1), a spindle assembly checkpoint (SAC) component, is a significant target due to its role in genomic fidelity during mitosis and its overexpression in several cancers. This review explores EGFR and MPS1 as therapeutic targets in HNC, analyzing their molecular mechanisms and the effects of their inhibition on cancer cells. It also highlights the promise of combinatorial approaches, such as microtubule-targeting agents (MTAs) and antimitotic agents, in improving HNC therapies, patient outcomes, and survival rates.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UNIPRO-Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, P…
- Medicine and Oral Surgery Department, University Institute of Health Sciences-CESPU (IUCS-CESPU), 4585-116 Gandra, Portugal.
- Associate Laboratory i4HB, Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, 4585-116 Gandra, Portugal.
- UCIBIO-Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal.
ORCID-Profile: Mafalda Calheiros-Lobo, João P N Silva, Bárbara Pinto, Luís Monteiro, Patrícia M A Silva, Hassan Bousbaa
Förderung
- Cooperativa de Ensino Superior Politécnico e Universitário Crl (CESPU)
- CESPU—Cooperativa de Ensino Superior Politécnico e Univer- sitário Crl
- CESPU
- Fundação para a Ciência e a Tecnologia (FCT)
Zitieren
APA
Calheiros-Lobo, M., Silva, J. P. N., Pinto, B., Monteiro, L., Silva, P. M. A., & Bousbaa, H. (2024). Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer. Pharmaceutics, 16(9), 1196. https://doi.org/10.3390/pharmaceutics16091196
Vancouver
Calheiros-Lobo M, Silva JPN, Pinto B, Monteiro L, Silva PMA, Bousbaa H. Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer. Pharmaceutics. 2024;16(9):1196. doi:10.3390/pharmaceutics16091196
BibTeX
@article{CalheirosLobo2024,
author = {Calheiros-Lobo, Mafalda and Silva, João P N and Pinto, Bárbara and Monteiro, Luís and Silva, Patrícia M A and Bousbaa, Hassan},
title = {Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {9},
pages = {1196},
doi = {10.3390/pharmaceutics16091196}
}
EUVIMED